Roman Topór-Mądry dismissed from post. MZ announces competition for AOTMiT president.

Roman Topor-Mądry has been removed from his position as president of the Agency for Health Technology Assessment and Tarification. Health Advocates Foundation President Marta Markiewicz was the first to report the news on X (formerly Twitter).

On November 13, the Health Ministry announced a call for applications for the post of president of the Agency for Health Technology Assessment and Tarification.

What requirements must a candidate for the position of AOTMiT president meet?

A candidate joining the recruitment for the post of President of the Agency should meet the following conditions, among others:

• Have a master's degree or equivalent in medical, pharmaceutical, economic, legal or technical sciences;
• Have knowledge of health care and evaluation of health care services, pharmacoeconomics, health care financing systems and health economics;

The responsibilities of the position include:

1) managing the Agency and representing it externally;

2) implementation of the orders referred to in Article 31c, paragraph 1 and Article 31f, paragraph 5 of the Law;

3) issuance of the recommendations referred to in Article 48aa (5) and (6) of the Law;

4) issuance of the opinion referred to in Article 48a, paragraph 4 of the Law;

5) Establishment of lists pursuant to Article 40a (2) and (8) of the Law of May 12, 2011 on Reimbursement of Drugs, Foodstuffs for Special Dietary Purposes and Medical Devices (Journal of Laws of 2023, item 826, as amended), hereinafter referred to as the "Reimbursement Law";

6) monitoring the efficiency and quality of the pharmacotherapy process on the basis of data received from the entity obliged to finance healthcare services from public funds;

7) to provide an opinion on the draft national transformation plan referred to in Article 95b, paragraph 1 of the Law;

8) submission of calculations referred to in Article 36 (1) of the Law of March 9, 2023 on the National Oncology Network (Journal of Laws of 2023, item 650) to the National Health Fund;

9) Issuing opinions referred to in Article 15 (3) of the aforementioned Law on Reimbursement of Drugs, Foodstuffs for Special Dietary Purposes and Medical Devices;

10) Issuing opinions on descriptions of drug programs referred to in Article 16a (1) of the aforementioned Law on Reimbursement of Drugs, Foodstuffs for Special Dietary Purposes and Medical Devices;

11) Preparation of the list referred to in Article 30a (2) of the aforementioned Law on Reimbursement of Drugs, Foodstuffs for Special Dietary Purposes and Medical Devices;

12) evaluation of the documentation referred to in Article 35 (8c) of the aforementioned Law on Reimbursement of Drugs, Foodstuffs for Special Dietary Purposes and Medical Devices;

13) Cooperation with the National Health Fund, the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, governmental and local governmental bodies and entities operating in other countries in the evaluation of health care services;

Source: MZ/X (formerly Twitter)